Simplify Logo
Indivior

Indivior

Pharma: treats addiction and mental illness

Automation & Controls Engineer

Full-Time
$98k - $115.5k/yr
Senior
Bachelor's, Associate's
Raleigh, NC, USA
In Person
No H1B Sponsorship

About the job

Requirements
  • A minimum of 5 years of experience in pharmaceutical or biotech good manufacturing practice manufacturing automation and controls, including hands-on programmable logic controller, supervisory control and data acquisition, human-machine interface programming, instrumentation, and troubleshooting.
  • Demonstrated experience with validation or computer software assurance of GxP computerized systems using GAMP 5, change control, deviations and corrective and preventive actions, and maintaining validated state.
  • Experience leading factory acceptance testing, site acceptance testing, and IQ/OQ/PQ for process equipment and utilities.
  • Familiarity with batch control using ISA-88, system integration using ISA-95, data integrity using ALCOA+, and 21 CFR Part 11 and Annex 11 compliance.
  • An associate's degree in a related field with 7 or more years of directly relevant GMP automation experience, or a high school diploma with 9 or more years of directly relevant GMP automation experience.
  • The employee must be legally authorized to work in the United States at the time of hire.
Responsibilities
  • Provide daily automation support for manufacturing and GMP utilities to ensure safe, compliant, and continuous operations; triage alarms; troubleshoot PLCs, HMIs, instrumentation, and networked controls; and resolve deviations to restore service and prevent recurrence.
  • Design, configure, and implement control system changes in PLC, SCADA, DCS, BMS, and EMS platforms in accordance with change-control, cybersecurity, and data-integrity requirements.
  • Lead or support automation scope for new equipment and modifications by authoring and reviewing URS, FS, and DS documents, participating in vendor selection, conducting FAT and SAT, and planning and executing IQ/OQ/PQ with Validation and Quality.
  • Own or support computer software assurance and computer system validation for GxP systems; develop risk assessments, test plans, traceability, and reports per GAMP 5 and site SOPs; and maintain the validated state through periodic review.
  • Develop and maintain automation standards, code libraries, alarm rationalization, and historian tags; and implement backups, disaster recovery, version control, and patch management.
  • Integrate and sustain data flows among MES/EBR, LIMS, historians, and enterprise systems to ensure ALCOA+ data integrity and timely release; and build dashboards for process monitoring, OEE, and deviation trending.
  • Partner with Manufacturing Science and Technology on transfer and scale-up; translate process requirements into control strategies, instrumentation specifications, interlocks, and recipes to achieve quality and yield targets.
  • Support root cause analysis as principal or co-investigator for automation-related deviations and equipment failures; author effective CAPAs and effectiveness checks; and implement error-proofing and alarm-management improvements.
  • Oversee automation aspects of critical utilities and facilities, including cleanroom HVAC, BMS/EMS, WFI, clean steam, compressed air, and CIP/SIP, to maintain environmental control and compliance with site classifications and monitoring.
  • Ensure compliance with FDA and EMA requirements, 21 CFR Part 11, Annex 11, data-integrity requirements, OSHA, and ISA/IEC 62443 cybersecurity practices; and maintain audit-ready documentation, drawings such as P&IDs and loop sheets, and SOPs.
  • Train operators, maintenance personnel, and peers on systems, SOPs, and troubleshooting, and provide on-call support coverage as needed for a small-site environment.
Desired Qualifications
  • Exposure to MES/EBR integration, historians such as OSIsoft PI/AVEVA, recipe management, and alarm rationalization.
  • Knowledge of operational-technology cybersecurity using ISA/IEC 62443 and GMP critical utilities, including BMS/EMS, WFI, clean steam, and cleanroom HVAC.

About the company

Indivior focuses on developing medicines for substance use disorders and serious mental illnesses. Its products are prescription pharmaceutical treatments, brought to market after research and development, and sold through healthcare professionals to patients worldwide. The company’s approach centers on patient safety, with ongoing monitoring and reporting of adverse events to ensure high-quality therapies. Compared with competitors, Indivior emphasizes targeted medicines for addiction and mental health, combining scientific R&D with a global commercialization presence to address critical healthcare needs. Its goal is to create sustainable value by improving patient outcomes and addressing unmet medical needs in global health.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Bon Air, Virginia

Founded

2014

Get referred to Indivior

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 raised guidance to $1.295 billion-$1.365 billion revenue and stronger EBITDA.
  • Q1 2026 SUBLOCADE revenue rose 32%, with record 31,800 new patient starts.
  • The merger creates 11 marketed medicines and targets $125 million annual cost savings.

What critics are saying

  • The August 2026 Supernus merger can still fail on stockholder, antitrust, or financing conditions.
  • Indivior still carries opioid-litigation accruals after the March 2026 settlement, preserving cash drag.
  • Closing in Q4 2026 ends Indivior as a standalone employer; duplicate roles disappear fast.

What makes Indivior unique

  • SUBLOCADE reached 500,000 patients by Q1 2026, anchoring Indivior's OUD franchise.
  • August 2026 merger gives Indivior majority control of a $2.2 billion CNS platform.
  • Indivior's March 2026 correctional-care study with NCCHC spotlights prison MOUD expertise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Holidays

Paid Sick Leave

Flexible Work Hours

Remote Work Options

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Adoption Assistance

Tuition Reimbursement

Employee Stock Purchase Plan

401(k) Company Match

Profit Sharing

Legal Services

Pet Insurance

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Mining Press Releases
Aug 26th, 2026
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027.

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it's At the Market (ATM) offering agreement with H.C. Wainwright & Co. Following the reported sale of these ADSs, Addex's cash runway has been extended to the fourth quarter of 2027. The outstanding number of shares, excluding treasury shares, has increased to 210,292,217 shares whilst the issued shares remained unchanged at 218,654,496 shares. About Addex Therapeutics: Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange. For more information, visit www.addextherapeutics.com. Contacts: | Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 [email protected] | Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 [email protected] | Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

BizWire Express
Aug 3rd, 2026
BizWire Express > - Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

BizWire Express - Bringing you the latest news as it happens from all over the world.

Finimize
Aug 3rd, 2026
Supernus and Indivior agree to an all-stock merger.

Supernus and Indivior agree to an all-stock merger. Indivior plans a $1 billion special dividend before closing, with the combined company set to trade as SUPN and target $125 million in annual cost savings. about 1 hour ago - 1 min What's going on here? Supernus Pharmaceuticals and Indivior said Monday they'll merge in a tax-free, all-stock deal, but Indivior plans to send shareholders a $1 billion special dividend before the tie-up closes in Q4. What does this mean? Both boards have unanimously approved the merger, which values the combined company around scale and efficiency rather than a simple cash takeover. Under the terms, Supernus shareholders will receive 1.5401 Indivior shares per Supernus share, leaving Indivior owners with about 56.5% of the new business. Indivior will also pay a one-time $1 billion dividend before closing, partly funded by a new $650 million term loan - a way to return cash now w... Keep reading for free. This content is free, but you must be logged in to continue reading. Already have an account?

Yahoo Finance
Aug 3rd, 2026
Supernus reports 32% revenue jump to $219M, announces merger with Indivior

Supernus Pharmaceuticals reported total revenues of $219.1 million for Q2 2026, up 32% year-over-year. Combined revenues from the company's four growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—reached $175.7 million, marking a 52% increase compared to Q2 2025. ONAPGO generated $13.5 million in net product sales during the quarter. Since launching in April 2025, the product has attracted approximately 2,600 enrollment forms from around 720 prescribers through end-July 2026. ZURZUVAE collaboration revenue totalled $35.4 million in Q2 2026, representing 50% of Biogen's net revenues for the product. US sales of ZURZUVAE increased approximately 53% year-over-year. Supernus raised its full-year 2026 financial guidance and announced a merger agreement with Indivior Pharmaceuticals to create a diversified CNS biopharmaceutical company.

Minichart
Aug 3rd, 2026
Supernus Pharmaceuticals Reports 32% Revenue Surge, Raises Guidance, and Announces Merger with Indivior Pharmaceuticals in Q2 2026

Supernus Pharmaceuticals Q2 2026 Earnings & Major Merger Announcement